Tag: Cancer survival

Adjuvant therapy has become a cornerstone of modern cancer treatment, representing a proactive strategy to improve long-term patient outcomes. The best reason to administer adjuvant therapy is to eradicate microscopic cancer cells that remain after primary treatment, effectively reducing the risk of cancer recurrence.

Based on 10-year follow-up data for metastatic melanoma, 34% of patients treated with Keytruda were still alive, demonstrating a sustained overall survival benefit. The length of time Keytruda can extend life depends heavily on various factors, including the type of cancer, its stage, and the patient's individual response to the immunotherapy.